Sentinel Lymph Nodes in Cutaneous Melanoma

Area of Science:

• Oncology
• Surgical Pathology

Background:

• Sentinel lymph node biopsy (SLNB) is the standard for early staging in cutaneous melanoma patients.
• SLNs are the most probable sites for melanoma metastasis.
• Current protocols involve formalin-fixed, paraffin-embedded sections with H&E and immunohistochemistry.

Purpose of the Study:

• To review the role and methods of sentinel lymph node examination in cutaneous melanoma staging.
• To highlight the prognostic significance of quantifying tumor burden in SLNs.

Main Methods:

• Review of standard pathological processing for SLNs.
• Description of histological and immunohistochemical techniques.
• Discussion of tumor burden quantification methods.

Main Results:

• Approximately 20% of cutaneous melanoma patients have melanoma cells detected in SLNs.
• SLNB allows for more intensive examination of high-risk nodes.
• Quantification of tumor burden in SLNs offers clinically significant prognostic data.

Conclusions:

• Sentinel lymph node examination is a vital component of cutaneous melanoma management.
• Accurate staging and prognostic assessment rely on thorough SLN analysis.
• Further research into quantification methods can refine patient management.